Sotera Health Company (NASDAQ:SHC ) Q4 2024 Earnings Conference Call February 27, 2025 9:00 AM ET Company Participants Jason Peterson – Vice President of Investor Relations and Treasurer Michael Petras – Chairman and Chief Executive Officer Jon Lyons – Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Sean Dodge – RBC Capital Markets Luke Sergott – Barclays Casey Woodring – J.P. Morgan Brett Fishbin – KeyBanc Dave Windley – Jefferies Michael Polark – Wolfe Research Operator Good morning, and welcome to the Sotera Health Fourth Quarter and Full Year 2024 Conference Call.
Sotera Health Company (SHC) came out with quarterly earnings of $0.21 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.26 per share a year ago.
CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results.
CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025.
CLEVELAND, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, will hold an Investor Day in New York City where Sotera Health's management team will discuss the Company's strategic positioning and outline future growth plans. Management will take questions from a live audience during two question-and-answer sessions.
Sotera Health Company (NASDAQ:SHC ) Q3 2024 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Jason Peterson - VP & Treasurer Michael Petras - Chairman & CEO Jonathan Lyons - SVP & CFO Conference Call Participants Sean Dodge - RBC Capital Markets Patrick Donnelly - Citigroup Inc. Salem Salem - Barclays Brett Fishbin - KeyBanc Capital Markets Casey Woodring - J.P. Morgan Chase Jason Bednar - Piper Sandler Dave Windley - Jefferies Michael Polark - Wolfe Research Operator Good morning, and welcome to the Sotera Health Third Quarter 2024 Conference Call.
Sotera Health Company (SHC) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.21 per share a year ago.
CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three and nine months ended September 30, 2024.
CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results.
CLEVELAND, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. It is expected that, as a result of the Offering, the Company's sponsors (affiliates of Warburg Pincus and GTCR) will cease to own a majority of the Company's outstanding common stock, which will affect certain sponsor rights and related matters. These rights are described in the Company's most recently filed annual general meeting proxy statement. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registration Rights Agreement.